News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amarin Corporation PLC (AMRN) Announces Submission of a Supplemental New Drug Application for BASF as Additional Vascepa® Active Pharmaceutical Ingredient Supplier



1/2/2013 9:22:37 AM

BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the late December 2012 submission of a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for BASF as an additional Vascepa® (icosapent ethyl) active pharmaceutical ingredient (API) supplier.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES